Taysha Gene Therapies (TSHA) Cash from Financing Activities (2020 - 2026)

Taysha Gene Therapies has reported Cash from Financing Activities for 7 years, with the latest figure at $711000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 1467.31% year-over-year to $711000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.4 million (up 259.21% YoY) and the FY2025 annual result came in at $274.6 million, up 258.08% from the prior year.
• Cash from Financing Activities fell to $711000.0 in Q1 2026 per TSHA's latest filing, from $49.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $216.3 million in Q2 2025 and troughed at -$4.2 million in Q4 2023.
• A 5-year average of $31.8 million and a median of $711000.0 in 2026 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 136637.86% in 2023, down 245.79% in 2023.
• Over 5 years, Cash from Financing Activities stood at $41.2 million in 2022, then tumbled by 110.3% to -$4.2 million in 2023, then soared by 91.6% to -$357000.0 in 2024, then jumped by 13981.23% to $49.6 million in 2025, then slumped by 98.57% to $711000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $711000.0, $49.6 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.